| Not Yet Recruiting | Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases NCT07454668 | Baptist Health South Florida | Phase 1 |
| Not Yet Recruiting | Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain M NCT07178938 | MedSIR | Phase 2 |
| Not Yet Recruiting | RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or NCT07413939 | Hoffmann-La Roche | Phase 2 / Phase 3 |
| Not Yet Recruiting | Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer NCT07217990 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With NCT07518173 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study NCT07417241 | Peking University Cancer Hospital & Institute | Phase 2 |
| Not Yet Recruiting | Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Ca NCT07470203 | Peking University Cancer Hospital & Institute | — |
| Recruiting | HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce NCT07459673 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Im NCT04273555 | University of Alabama at Birmingham | Phase 1 / Phase 2 |
| Recruiting | HER2 Vaccine for Locally Advanced Breast Cancer NCT06949410 | Pravin T.P Kaumaya | Phase 1 |
| Recruiting | IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast NCT07377643 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Phase 3 |
| Recruiting | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC NCT07510802 | Beijing Biotech | Phase 1 / Phase 2 |
| Recruiting | Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) NCT07486089 | Beijing Biotech | Phase 1 / Phase 2 |
| Not Yet Recruiting | RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure NCT07366840 | Fudan University | Phase 2 / Phase 3 |
| Recruiting | A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients NCT07281001 | Blokhin's Russian Cancer Research Center | N/A |
| Not Yet Recruiting | T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis NCT07152782 | Fudan University | Phase 2 |
| Not Yet Recruiting | Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herom NCT07198672 | Zhenzhen Liu | N/A |
| Recruiting | A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive NCT07102381 | Jazz Pharmaceuticals | Phase 2 |
| Recruiting | A Study of Surgery and Radiotherapy in People With Breast Cancer NCT07053085 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Recepto NCT07043725 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | HB1801 Combined Treatment of HER2-positive Breast Cancer NCT07116824 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II St NCT07179939 | Fudan University | Phase 2 |
| Not Yet Recruiting | This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Moni NCT06973525 | Hebei Medical University Fourth Hospital | Phase 2 |
| Withdrawn | Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer NCT04419181 | University of Rochester | Phase 2 |
| Recruiting | Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients NCT06892093 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N/A |
| Recruiting | A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined Wi NCT06992882 | Fudan University | Phase 3 |
| Not Yet Recruiting | Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer NCT07019337 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Not Yet Recruiting | Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebe NCT07019272 | Hebei Medical University Fourth Hospital | — |
| Recruiting | A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Thera NCT06891833 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 / Phase 3 |
| Recruiting | A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasi NCT06830889 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer NCT07358182 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Active Not Recruiting | HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy NCT06844669 | Washington University School of Medicine | Phase 2 |
| Not Yet Recruiting | Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemother NCT06868017 | The First Hospital of Jilin University | Phase 4 |
| Recruiting | Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and A NCT06348134 | University of Chicago | Phase 2 |
| Recruiting | NearWave Optical Molecular Monitoring NCT06744465 | Indiana University | N/A |
| Recruiting | Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. NCT06450314 | UNICANCER | Phase 2 |
| Completed | Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxteca NCT06833268 | Daiichi Sankyo | — |
| Recruiting | HER-2 B Cell Peptide Vaccine NCT06414733 | Pravin T.P Kaumaya | Phase 1 |
| Recruiting | Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer NCT07233499 | Ain Shams University | Phase 2 |
| Not Yet Recruiting | Pyrotinib in HER2-positive Early Breast Cancer NCT06718335 | Nie Jianyun | N/A |
| Recruiting | Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer NCT06518382 | Giampaolo Bianchini | — |
| Recruiting | BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer NCT06441890 | University of Illinois at Chicago | Phase 2 |
| Recruiting | Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05) NCT06832904 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Recruiting | Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer NCT06446882 | Fundacio Clinic Barcelona | N/A |
| Recruiting | Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormo NCT06123988 | University of Miami | N/A |
| Active Not Recruiting | Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Ca NCT06068985 | Latin American Cooperative Oncology Group | Phase 2 |
| Not Yet Recruiting | T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer NCT06548178 | Fudan University | Phase 2 |
| Recruiting | The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer NCT06439693 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast C NCT06172127 | MedSIR | Phase 2 |
| Active Not Recruiting | TME Alteration in HER2 Positive Breast Cancer NCT06533670 | Seoul National University Hospital | — |
| Recruiting | A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Local NCT06445400 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer NCT06358625 | Center Eugene Marquis | — |
| Active Not Recruiting | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer NCT06328738 | Enliven Therapeutics | Phase 1 |
| Active Not Recruiting | A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positi NCT06316531 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Basket Study for Oligo-metastatic Breast Cancer NCT05982678 | The Netherlands Cancer Institute | Phase 2 |
| Recruiting | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditiona NCT06958627 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 / Phase 3 |
| Completed | HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada NCT06386263 | AstraZeneca | — |
| Active Not Recruiting | Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2- NCT06782698 | Centro Hospitalar Universitário de Santo António | N/A |
| Recruiting | A Phase 1/1b Study of IAM1363 in HER2 Cancers NCT06253871 | Iambic Therapeutics, Inc | Phase 1 |
| Recruiting | The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients. NCT06330012 | Samsung Medical Center | N/A |
| Recruiting | DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer NCT06313086 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 |
| Recruiting | Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patien NCT06479460 | The First Affiliated Hospital with Nanjing Medical University | — |
| Recruiting | Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer NCT06220214 | Alison Stopeck | EARLY_Phase 1 |
| Recruiting | RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study NCT07030569 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Active Not Recruiting | A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer NCT06265428 | DualityBio Inc. | Phase 3 |
| Terminated | Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer NCT05553522 | Baptist Health South Florida | Phase 1 |
| Recruiting | Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer NCT06276868 | Henan Cancer Hospital | Phase 2 |
| Recruiting | A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) NCT06210776 | Daiichi Sankyo | — |
| Recruiting | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treate NCT06217185 | Hebei Medical University Fourth Hospital | Phase 4 |
| Recruiting | Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer NCT05955170 | Institut Curie | Phase 2 |
| Recruiting | Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery NCT06281210 | European Institute of Oncology | N/A |
| Terminated | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer NCT05954143 | Bolt Biotherapeutics, Inc. | Phase 2 |
| Recruiting | Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HE NCT06016387 | Sunnybrook Health Sciences Centre | Phase 2 |
| Active Not Recruiting | Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-posit NCT05710666 | Cancer Trials Ireland | Phase 2 |
| Unknown | Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Th NCT06161922 | Fudan University | — |
| Recruiting | Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment NCT06087120 | Gene Solutions | — |
| Active Not Recruiting | De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer NCT07421141 | National Medical Research Radiological Centre of the Ministry of Health of Russia | Phase 2 |
| Recruiting | A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) NCT05809752 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Active Not Recruiting | A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic NCT06968585 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 3 |
| Unknown | Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunct NCT05880160 | University College, London | N/A |
| Completed | Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations NCT05904730 | Lynkcell Europe | Phase 1 |
| Withdrawn | Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response NCT05371860 | Armando Giuliano | Phase 2 |
| Unknown | 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study NCT05955833 | Amsterdam UMC, location VUmc | Phase 1 |
| Completed | Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB NCT07416409 | Deraya University | — |
| Recruiting | Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer NCT06035016 | Peking Union Medical College Hospital | — |
| Not Yet Recruiting | Thero2-01S22 in HER2-positive Breast Cancer NCT05698186 | Institut de cancérologie Strasbourg Europe | Phase 3 |
| Recruiting | Study of 68Ga /131I SGMIB-ZT-199 PET Imaging Targeting HER2-positive in the Diagnosis of Metastatic Breast Can NCT05982626 | Huashan Hospital | N/A |
| Recruiting | TRUDI: TDXD+Durva in HER2+/Low IBC NCT05795101 | Filipa Lynce, MD | Phase 2 |
| Recruiting | Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC NCT05918328 | Henan Cancer Hospital | Phase 2 |
| Active Not Recruiting | STOP-HER2: Stopping Trastuzumab in HER2+ MBC NCT05721248 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer NCT05020860 | Baylor Breast Care Center | Phase 2 |
| Recruiting | Pyrotinib in Women With High-risk in Early Stage Breast Cancer NCT05834764 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive NCT05635487 | Shengjing Hospital | Phase 2 |
| Completed | A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-p NCT05769751 | Daiichi Sankyo | — |
| Recruiting | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Posi NCT05760612 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 |
| Recruiting | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Brea NCT05705401 | NRG Oncology | Phase 3 |
| Terminated | Tucatinib Together With Pembrolizumab and Trastuzumab NCT04789096 | Breast Cancer Trials, Australia and New Zealand | Phase 2 |
| Recruiting | PRE-I-SPY Phase I/Ib Oncology Platform Program NCT05868226 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Recruiting | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 NCT05514717 | Mersana Therapeutics | Phase 1 |
| Unknown | A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Canc NCT05692661 | Shanghai Proton and Heavy Ion Center | Phase 1 |
| Unknown | Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer NCT05720026 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 |
| Recruiting | Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Canc NCT05306041 | GBG Forschungs GmbH | Phase 2 |
| Recruiting | Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA I NCT07073755 | Hunan Cancer Hospital | — |
| Not Yet Recruiting | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C) NCT05388500 | Institut de cancérologie Strasbourg Europe | Phase 3 |
| Recruiting | Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease NCT05388149 | University Health Network, Toronto | Phase 2 |
| Completed | EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients NCT05458401 | Daiichi Sankyo | — |
| Recruiting | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 | Fudan University | Phase 2 |
| Terminated | Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors NCT05511844 | Orum Therapeutics USA, Inc. | Phase 1 |
| Unknown | Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer NCT05561686 | Hunan Cancer Hospital | — |
| Unknown | Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Canc NCT04997798 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Active Not Recruiting | Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Nerati NCT05252988 | Spanish Breast Cancer Research Group | Phase 2 |
| Terminated | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors NCT05555251 | BioInvent International AB | Phase 1 / Phase 2 |
| Recruiting | Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast NCT04886531 | Ruth O'Regan | Phase 2 |
| Completed | A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Ner NCT05599334 | Pierre Fabre Medicament | — |
| Unknown | Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-I NCT05429294 | First Affiliated Hospital Xi'an Jiaotong University | Phase 2 |
| Withdrawn | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cance NCT04512261 | Reva Basho | Phase 1 / Phase 2 |
| Recruiting | Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ M NCT05378464 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY St NCT05433753 | National Cancer Center, Japan | — |
| Active Not Recruiting | A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and NCT05426486 | Caigang Liu | Phase 2 / Phase 3 |
| Completed | Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Tw NCT05253911 | iOMEDICO AG | — |
| Withdrawn | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer NCT05227131 | MedSIR | Phase 2 |
| Withdrawn | A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Canc NCT05474690 | Henan Cancer Hospital | Phase 3 |
| Unknown | PIK3CA in HER2+ BC and pCR Trial NCT05750693 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Completed | 99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Th NCT05412459 | Tomsk National Research Medical Center of the Russian Academy of Sciences | — |
| Unknown | DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer NCT05334810 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positi NCT05346224 | Shanghai Henlius Biotech | Phase 3 |
| Recruiting | Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI NCT04332588 | University of Alabama at Birmingham | Phase 1 |
| Active Not Recruiting | A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer NCT05132582 | Seagen, a wholly owned subsidiary of Pfizer | Phase 3 |
| Unknown | A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC NCT05945368 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Terminated | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Can NCT05091528 | Silverback Therapeutics | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer NCT05189067 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 / Phase 3 |
| Terminated | De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo NCT04675827 | Jules Bordet Institute | Phase 2 |
| Active Not Recruiting | Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer NCT05169853 | Ain Shams University | — |
| Unknown | Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer NCT05154396 | Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Study of Screening Brain MRIs in Stage IV Breast Cancer NCT05115474 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Recruiting | Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Settin NCT04638725 | Institut de cancérologie Strasbourg Europe | — |
| Completed | HER2-directed Biosimilar in Breast Cancer: Real World ePRO NCT05234021 | OnkoZentrum Zürich AG | — |
| Completed | Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer NCT05149014 | Daiichi Sankyo France | — |
| Unknown | RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer NCT05134519 | Xijing Hospital | Phase 2 |
| Recruiting | Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab NCT05325632 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Unknown | Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast NCT05076695 | Fudan University | Phase 2 |
| Unknown | Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude NCT05063643 | Affiliated Hospital of Qinghai University | — |
| Unknown | TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) NCT04760431 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer NCT05406635 | Odense University Hospital | N/A |
| Active Not Recruiting | Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases NCT04899908 | Brigham and Women's Hospital | Phase 2 |
| Unknown | Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab NCT05346861 | Fudan University | Phase 3 |
| Active Not Recruiting | Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxici NCT05036252 | Memorial Sloan Kettering Cancer Center | — |
| Withdrawn | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With NCT04602117 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Unknown | Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) NCT05036005 | Institut fuer Frauengesundheit | Phase 4 |
| Recruiting | ATEMPT 2.0: Adjuvant T-DM1 vs TH NCT04893109 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC NCT06754059 | zhangjie | — |
| Active Not Recruiting | Exosome as the Prognostic and Predictive Biomarker in EBC Patients NCT05955521 | Samsung Medical Center | N/A |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Unknown | Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Canc NCT05912062 | Institut Català d'Oncologia | — |
| Unknown | Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy NCT05019365 | University of Glasgow | — |
| Recruiting | Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer NCT04993014 | AC Camargo Cancer Center | Phase 2 |
| Withdrawn | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advance NCT04464967 | NKGen Biotech, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors NCT04660929 | Carisma Therapeutics Inc | Phase 1 |
| Active Not Recruiting | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anato NCT04569747 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis NCT04639271 | Shandong Cancer Hospital and Institute | Phase 2 |
| Unknown | Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC NCT04609540 | Shandong Cancer Hospital and Institute | — |
| Completed | Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer NCT07115095 | Nanlin Li | N/A |
| Recruiting | Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease NCT04588545 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Suspended | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive So NCT04650451 | Bellicum Pharmaceuticals | Phase 1 |
| Completed | A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer NCT04539938 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Unknown | CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC NCT04457700 | Peking University | — |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Unknown | Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and NCT05985187 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Completed | Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors NCT04487236 | Suzhou Zanrong Pharma Limited | Phase 1 |
| Terminated | Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete NCT04578106 | Fundacio Clinic Barcelona | Phase 2 |
| Active Not Recruiting | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Facto NCT05593094 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Terminated | The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Pati NCT03619044 | Institut Claudius Regaud | N/A |
| Recruiting | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer NCT04360941 | Royal Marsden NHS Foundation Trust | Phase 1 |
| Completed | TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer NCT04246671 | Bavarian Nordic | Phase 1 |
| Active Not Recruiting | MARGetuximab Or Trastuzumab (MARGOT) NCT04425018 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors NCT04450732 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Phase 1 |
| Recruiting | Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer NCT04481932 | Peking University | Phase 2 |
| Not Yet Recruiting | Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast NCT04337658 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 3 |
| Completed | Real World Study on the Efficacy and Safety of Anti-HER2 Therapy NCT05367739 | Hunan Cancer Hospital | — |
| Withdrawn | Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer NCT04142554 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Not Yet Recruiting | Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer NCT04158856 | xuexin he | Phase 2 |
| Completed | DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease NCT04420598 | MedSIR | Phase 2 |
| Unknown | Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastati NCT04605575 | Sun Yat-sen University | Phase 2 |
| Unknown | A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 A NCT04158947 | xuexin he | Phase 2 |
| Recruiting | Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breas NCT04281641 | Fudan University | N/A |
| Unknown | Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer NCT04158505 | Chinese Academy of Medical Sciences | — |
| Terminated | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Exp NCT04278144 | Bolt Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER NCT04236310 | Ruijin Hospital | Phase 2 |
| Unknown | Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases NCT04582968 | Fudan University | Phase 1 / Phase 2 |
| Unknown | PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer NCT05346107 | Xijing Hospital | Phase 2 |
| Not Yet Recruiting | Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy NCT04225858 | The Netherlands Cancer Institute | N/A |
| Unknown | A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients NCT04288141 | King's College London | — |
| Unknown | Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer NCT03698383 | Korean Cancer Study Group | Phase 2 |
| Active Not Recruiting | Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer NCT03879577 | University of Chicago | Phase 2 |
| Recruiting | fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases NCT06328465 | European Institute of Oncology | N/A |
| Terminated | Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive B NCT04042051 | Cancer Trials Ireland | Phase 1 |
| Unknown | Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer NCT04088110 | Fuzhou General Hospital | Phase 2 |
| Active Not Recruiting | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advan NCT03975647 | Seagen, a wholly owned subsidiary of Pfizer | Phase 3 |
| Unknown | A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated A NCT04095390 | Jinming Yu | Phase 2 |
| Unknown | TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer NCT04094896 | Guangdong Provincial People's Hospital | Phase 2 |
| Unknown | KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer NCT04034823 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Completed | Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protoc NCT04109391 | Tanvex BioPharma USA, Inc. | Phase 3 |
| Completed | Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer NCT03981705 | Masonic Cancer Center, University of Minnesota | — |
| Recruiting | Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer NCT04030507 | Brigham and Women's Hospital | N/A |
| Unknown | Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negativ NCT03812393 | West Cancer Center | Phase 2 |
| Terminated | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular I NCT04106167 | Fate Therapeutics | — |
| Unknown | Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast NCT03913234 | Yonsei University | Phase 1 / Phase 2 |
| Unknown | Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast NCT03947242 | Henan Cancer Hospital | N/A |
| Unknown | Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC NCT03910712 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery NCT03881878 | Samsung Medical Center | Phase 1 / Phase 2 |
| Terminated | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast NCT03894007 | Renske Altena | Phase 2 |
| Unknown | Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Explora NCT03919253 | Hebei Medical University Fourth Hospital | Phase 2 |
| Completed | To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer NCT03644186 | ETOP IBCSG Partners Foundation | Phase 2 |
| Unknown | Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer NCT03907800 | Ruijin Hospital | Phase 2 |
| Completed | B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer NCT03953833 | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1 |
| Unknown | Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Canc NCT03933319 | Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer NCT03847818 | Shandong University | N/A |
| Completed | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumo NCT03841110 | Fate Therapeutics | Phase 1 |
| Active Not Recruiting | Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] NCT03747120 | University of Texas Southwestern Medical Center | Phase 2 |
| Terminated | Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 NCT03630809 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer NCT06693024 | Shu Wang | — |
| Recruiting | Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients NCT06722599 | Shu Wang | — |
| Recruiting | Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast C NCT06722612 | Shu Wang | — |
| Recruiting | Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherap NCT06711068 | Shu Wang | — |
| Recruiting | Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy NCT06693037 | Shu Wang | — |
| Withdrawn | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously NCT03811418 | iOMEDICO AG | Phase 3 |
| Unknown | Tw HER2 Positive Breast Cancer Productivity & Utility Study NCT04011085 | Taiwan Epidemiology Association | — |
| Completed | Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patient NCT03755141 | National Cancer Center, Korea | Phase 2 |
| Completed | T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer NCT03530696 | University of Arizona | Phase 2 |
| Completed | Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer P NCT03735966 | Henan Cancer Hospital | Phase 2 |
| Active Not Recruiting | MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or NCT03881605 | Sunnybrook Health Sciences Centre | N/A |
| Unknown | Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant ) NCT04033172 | Chinese Academy of Medical Sciences | Phase 2 |
| Terminated | Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Meta NCT03709082 | University of Kansas Medical Center | Phase 1 / Phase 2 |
| Completed | Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and N NCT03094052 | University of California, San Francisco | Phase 2 |
| Unknown | Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy NCT03684863 | Shandong Cancer Hospital and Institute | Phase 2 |
| Completed | 18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response NCT04756921 | Biyun Wang, MD | — |
| Active Not Recruiting | HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases NCT03696030 | City of Hope Medical Center | Phase 1 |
| Unknown | A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer NCT03655353 | Henrik Lindman | N/A |
| Completed | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors NCT03650348 | Pieris Pharmaceuticals, Inc. | Phase 1 |
| Completed | Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer NCT04957212 | Cinnagen | Phase 3 |
| Active Not Recruiting | Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cance NCT03571633 | Centre Leon Berard | Phase 2 |
| Completed | Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer NCT03588091 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Completed | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Ge NCT03602079 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Completed | Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer NCT03556358 | Tanvex BioPharma USA, Inc. | Phase 3 |
| Active Not Recruiting | HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer NCT03387553 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Completed | Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combi NCT06107790 | Zhejiang Hisun Pharmaceutical Co. Ltd. | Phase 3 |
| Terminated | Adapted Physical Activity for Breast Cancer HER2 Positive Patient NCT02963363 | Centre Jean Perrin | N/A |
| Unknown | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or NCT03500380 | RemeGen Co., Ltd. | Phase 2 / Phase 3 |
| Unknown | Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy NCT04276337 | Samsung Medical Center | — |
| Active Not Recruiting | Omission of Radiation in Patients With Her-2 Positive Breast Cancer NCT03460067 | University of Kansas Medical Center | N/A |
| Active Not Recruiting | Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer NCT03384914 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early B NCT03013504 | Prestige Biopharma Limited | Phase 3 |
| Completed | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors NCT03319459 | Fate Therapeutics | Phase 1 |
| Completed | Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients NCT03281824 | Alteogen, Inc. | Phase 1 |
| Unknown | Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cance NCT03521245 | OmicsWay Corp. | — |
| Completed | PRS-343 in HER2-Positive Solid Tumors NCT03330561 | Pieris Pharmaceuticals, Inc. | Phase 1 |
| Unknown | Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Canc NCT03238495 | Qamar Khan | Phase 2 |
| Active Not Recruiting | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast NCT03179904 | Mayo Clinic | Phase 2 |
| Completed | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer NCT03112590 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 NCT03125928 | Fox Chase Cancer Center | Phase 2 |
| Unknown | A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin NCT03085368 | Peking Union Medical College Hospital | Phase 2 / Phase 3 |
| Completed | Denosumab as an add-on Neoadjuvant Treatment (GeparX) NCT02682693 | GBG Forschungs GmbH | Phase 2 |
| Completed | TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer NCT03140553 | Guangdong Provincial People's Hospital | Phase 2 |
| Terminated | Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer NCT07166367 | National Cancer Centre, Singapore | Phase 2 |
| Completed | Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study NCT02705859 | Cancer Trials Ireland | Phase 1 |
| Completed | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2 NCT02614794 | Seagen Inc. | Phase 2 |
| Completed | Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer NCT02476539 | Tianjin Hemay Pharmaceutical Co., Ltd | Phase 1 |
| Active Not Recruiting | A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging NCT02993198 | Northwestern University | Phase 2 |
| Completed | A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer NCT02362958 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patien NCT02226276 | City of Hope Medical Center | N/A |
| Recruiting | De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients NCT06700369 | Shu Wang | — |
| Recruiting | Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer NCT06711055 | Shu Wang | — |
| Completed | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treat NCT02125344 | GBG Forschungs GmbH | Phase 3 |
| Terminated | Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy NCT02345772 | Western Regional Medical Center | Phase 1 / Phase 2 |
| Terminated | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advan NCT02213744 | Merrimack Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx NCT02038010 | Northwestern University | Phase 1 |
| Completed | Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Pos NCT02060253 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection NCT04170595 | Genor Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Patients With Brain Metastases From HER2-positive Breast Cancer NCT02135159 | Institut du Cancer de Montpellier - Val d'Aurelle | Phase 1 |
| Terminated | PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer NCT01712815 | University of Southern California | N/A |
| Completed | Cardiac Safety Study in Patients With HER2 + Breast Cancer NCT01904903 | Medstar Health Research Institute | Phase 2 |
| Completed | Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast C NCT01855828 | Yale University | Phase 2 |
| Terminated | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locall NCT01912963 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy NCT03738553 | University of Washington | — |
| Terminated | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive NCT01873833 | University of Southern California | Phase 2 |
| Active Not Recruiting | Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With NCT01730833 | City of Hope Medical Center | Phase 2 |
| Completed | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer Wi NCT01783756 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Pre Operative Trastuzumab in Operable Breast Cancer NCT01785420 | Dr Rajendra A. Badwe | Phase 3 |
| Terminated | Fasting on Newly Diagnosed Breast Cancer NCT02379585 | Western Regional Medical Center | Phase 1 / Phase 2 |
| Terminated | Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer NCT01729884 | University of Washington | Phase 2 |
| Completed | Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer NCT01840306 | Cancer Trials Ireland | — |
| Terminated | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Meta NCT01705340 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer NCT01632332 | Mayo Clinic | Phase 1 |
| Terminated | CharactHer. ICORG 12-09, V3 NCT01722890 | Cancer Trials Ireland | — |
| Completed | Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer NCT01688609 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HE NCT01219907 | University of Washington | Phase 1 |
| Terminated | HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025 NCT02095210 | Dorte Nielsen | Phase 1 |
| Completed | Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER NCT01355393 | University of Washington | Phase 1 / Phase 2 |
| Completed | Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tu NCT01245205 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379 | QuantumLeap Healthcare Collaborative | Phase 2 |